Table 2:
Proportion of patients with MDR UTI and UTI at each post-procedure time-point and Total UTIs
| Proportion of patients with MDR UTI and UTI | Total UTI and MDR UTI** | ||||
|---|---|---|---|---|---|
| BTX* N=28 | SNM* N=73 | p-value | BTX | SNM | |
| MDR UTI | - | - | - | - | |
| 0–4 weeks | 0 (0) | 0 (0) | 1.00 | 0 | 0 |
| 4–12 weeks | 0 (0) | 0 (0) | 1.00 | 0 | 0 |
| 3–6 months | 0 (0) | 0 (0) | 1.00 | 0 | 0 |
| 6–12 months | 0 (0) | 1 (1.4) | 1.00 | 0 | 1 |
| Cumulative (0–12 mo) | 0 (0) | 1 (1.4) | 1.00 | 0 | 1 |
| All treated UTI | - | - | - | - | |
| 0–4 weeks | 3 (10.7) | 3 (4.1) | 0.34 | 3 | 3 |
| 4–12 weeks | 3 (10.7) | 4 (5.5) | 0.39 | 4 | 4 |
| 3–6 months | 5 (17.9) | 11 (15.1) | 0.76 | 6 | 15 |
| 6–12 months | 4 (14.3) | 19 (26.0) | 0.21 | 6 | 25 |
| Cumulative (0–12 mo) | 11 (39.3) | 27 (37.0) | 0.83 | 20 | 48 |
*
Results reported as N (%)
**
Results reported as N; each patient may have had >1 UTI during each time-point.
Abbreviations: UTI (urinary tract infection); MDR (multidrug resistant); BTX (intradetrusor onabotulinumtoxinA); SNM (sacral neuromodulation)